Annual EBIT
-$460.56 M
-$61.68 M-15.46%
31 December 2023
Summary:
Iovance Biotherapeutics annual earnings before interest & taxes is currently -$460.56 million, with the most recent change of -$61.68 million (-15.46%) on 31 December 2023. During the last 3 years, it has fallen by -$198.62 million (-75.83%). IOVA annual EBIT is now -2914830.38% below its all-time high of -$14.40 thousand.IOVA EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$89.07 M
+$12.85 M+12.61%
30 September 2024
Summary:
Iovance Biotherapeutics quarterly earnings before interest & taxes is currently -$89.07 million, with the most recent change of +$12.85 million (+12.61%) on 30 September 2024. Over the past year, it has increased by +$29.29 million (+24.75%). IOVA quarterly EBIT is now -1859.63% below its all-time high of $5.06 million, reached on 31 December 2012.IOVA Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$429.96 M
+$29.29 M+6.38%
30 September 2024
Summary:
Iovance Biotherapeutics TTM earnings before interest & taxes is currently -$429.96 million, with the most recent change of +$29.29 million (+6.38%) on 30 September 2024. Over the past year, it has increased by +$16.38 million (+3.67%). IOVA TTM EBIT is now -10609.36% below its all-time high of $4.09 million, reached on 31 March 2013.IOVA TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IOVA EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -15.5% | +24.8% | +3.7% |
| 3 y3 years | -75.8% | -3.3% | -37.9% |
| 5 y5 years | -259.1% | -72.6% | -143.3% |
IOVA EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -75.8% | at low | -3.3% | +26.6% | -37.9% | +8.0% |
| 5 y | 5 years | -259.1% | at low | -72.6% | +26.6% | -143.3% | +8.0% |
| alltime | all time | <-9999.0% | at low | -1859.6% | +26.6% | <-9999.0% | +8.0% |
Iovance Biotherapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$89.07 M(-12.6%) | -$429.96 M(-6.4%) |
| June 2024 | - | -$101.91 M(-13.4%) | -$459.25 M(-1.7%) |
| Mar 2024 | - | -$117.72 M(-2.9%) | -$467.43 M(+1.5%) |
| Dec 2023 | -$460.56 M(+15.5%) | -$121.26 M(+2.4%) | -$460.56 M(+3.2%) |
| Sept 2023 | - | -$118.36 M(+7.5%) | -$446.34 M(+4.2%) |
| June 2023 | - | -$110.09 M(-0.7%) | -$428.37 M(+2.5%) |
| Mar 2023 | - | -$110.86 M(+3.6%) | -$418.02 M(+4.8%) |
| Dec 2022 | -$398.88 M(+16.4%) | -$107.04 M(+6.6%) | -$398.88 M(+1.9%) |
| Sept 2022 | - | -$100.39 M(+0.7%) | -$391.31 M(+3.8%) |
| June 2022 | - | -$99.73 M(+8.7%) | -$377.15 M(+5.1%) |
| Mar 2022 | - | -$91.71 M(-7.8%) | -$358.85 M(+4.7%) |
| Dec 2021 | -$342.70 M(+30.8%) | -$99.47 M(+15.3%) | -$342.70 M(+9.9%) |
| Sept 2021 | - | -$86.24 M(+5.9%) | -$311.77 M(+9.6%) |
| June 2021 | - | -$81.43 M(+7.7%) | -$284.50 M(+6.7%) |
| Mar 2021 | - | -$75.57 M(+10.3%) | -$266.70 M(+1.8%) |
| Dec 2020 | -$261.94 M(+26.6%) | -$68.53 M(+16.2%) | -$261.94 M(+1.3%) |
| Sept 2020 | - | -$58.97 M(-7.3%) | -$258.51 M(+2.9%) |
| June 2020 | - | -$63.63 M(-10.1%) | -$251.16 M(+5.7%) |
| Mar 2020 | - | -$70.81 M(+8.8%) | -$237.70 M(+14.9%) |
| Dec 2019 | -$206.87 M(+61.3%) | -$65.11 M(+26.2%) | -$206.87 M(+17.1%) |
| Sept 2019 | - | -$51.61 M(+2.9%) | -$176.71 M(+10.3%) |
| June 2019 | - | -$50.16 M(+25.5%) | -$160.15 M(+13.3%) |
| Mar 2019 | - | -$39.99 M(+14.4%) | -$141.37 M(+10.2%) |
| Dec 2018 | -$128.26 M(+38.1%) | -$34.94 M(-0.3%) | -$128.26 M(+7.4%) |
| Sept 2018 | - | -$35.06 M(+11.7%) | -$119.39 M(+11.9%) |
| June 2018 | - | -$31.38 M(+16.7%) | -$106.67 M(+7.9%) |
| Mar 2018 | - | -$26.88 M(+3.1%) | -$98.87 M(+6.5%) |
| Dec 2017 | -$92.88 M(+73.2%) | -$26.07 M(+16.7%) | -$92.88 M(+12.3%) |
| Sept 2017 | - | -$22.34 M(-5.2%) | -$82.73 M(+4.2%) |
| June 2017 | - | -$23.58 M(+12.9%) | -$79.36 M(+17.6%) |
| Mar 2017 | - | -$20.88 M(+31.2%) | -$67.51 M(+25.9%) |
| Dec 2016 | -$53.64 M | -$15.92 M(-16.1%) | -$53.64 M(+16.1%) |
| Sept 2016 | - | -$18.98 M(+61.8%) | -$46.20 M(+32.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2016 | - | -$11.73 M(+67.3%) | -$34.86 M(+17.9%) |
| Mar 2016 | - | -$7.01 M(-17.3%) | -$29.57 M(+6.1%) |
| Dec 2015 | -$27.86 M(+131.4%) | -$8.48 M(+10.9%) | -$27.86 M(+14.9%) |
| Sept 2015 | - | -$7.64 M(+18.7%) | -$24.25 M(+24.9%) |
| June 2015 | - | -$6.44 M(+21.6%) | -$19.41 M(+28.7%) |
| Mar 2015 | - | -$5.30 M(+8.8%) | -$15.08 M(+25.2%) |
| Dec 2014 | -$12.04 M(-46.8%) | -$4.87 M(+73.7%) | -$12.04 M(-35.5%) |
| Sept 2014 | - | -$2.80 M(+32.8%) | -$18.67 M(-26.1%) |
| June 2014 | - | -$2.11 M(-6.6%) | -$25.28 M(-4.6%) |
| Mar 2014 | - | -$2.26 M(-80.3%) | -$26.49 M(+6.2%) |
| Dec 2013 | -$22.64 M(+2450.5%) | -$11.50 M(+22.2%) | -$24.94 M(+197.7%) |
| Sept 2013 | - | -$9.41 M(+183.0%) | -$8.38 M(-1828.4%) |
| June 2013 | - | -$3.33 M(+371.7%) | $484.70 K(-88.2%) |
| Mar 2013 | - | -$704.90 K(-113.9%) | $4.09 M(-560.7%) |
| Dec 2012 | -$887.70 K(-95.7%) | $5.06 M(-1025.4%) | -$888.10 K(-90.3%) |
| Sept 2012 | - | -$547.00 K(-294.4%) | -$9.18 M(-36.3%) |
| June 2012 | - | $281.40 K(-105.0%) | -$14.42 M(-42.9%) |
| Mar 2012 | - | -$5.68 M(+75.9%) | -$25.26 M(+24.8%) |
| Dec 2011 | -$20.54 M(+2419.3%) | -$3.23 M(-44.2%) | -$20.24 M(+15.6%) |
| Sept 2011 | - | -$5.79 M(-45.2%) | -$17.50 M(+47.3%) |
| June 2011 | - | -$10.56 M(+1504.3%) | -$11.88 M(+745.1%) |
| Mar 2011 | - | -$658.30 K(+32.7%) | -$1.41 M(+72.4%) |
| Dec 2010 | -$815.40 K(+5060.8%) | -$496.10 K(+197.1%) | -$815.40 K(+153.5%) |
| Sept 2010 | - | -$167.00 K(+97.4%) | -$321.60 K(+103.4%) |
| June 2010 | - | -$84.60 K(+25.0%) | -$158.10 K(+105.9%) |
| Mar 2010 | - | -$67.70 K(+2843.5%) | -$76.80 K(+389.2%) |
| Dec 2009 | -$15.80 K(-72.3%) | -$2300.00(-34.3%) | -$15.70 K(-43.3%) |
| Sept 2009 | - | -$3500.00(+6.1%) | -$27.70 K(+3.7%) |
| June 2009 | - | -$3300.00(-50.0%) | -$26.70 K(-30.5%) |
| Mar 2009 | - | -$6600.00(-53.8%) | -$38.40 K(-32.7%) |
| Dec 2008 | -$57.10 K | -$14.30 K(+472.0%) | -$57.10 K(+33.4%) |
| Sept 2008 | - | -$2500.00(-83.3%) | -$42.80 K(+6.2%) |
| June 2008 | - | -$15.00 K(-40.7%) | -$40.30 K(+59.3%) |
| Mar 2008 | - | -$25.30 K | -$25.30 K |
FAQ
- What is Iovance Biotherapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics annual EBIT year-on-year change?
- What is Iovance Biotherapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics quarterly EBIT year-on-year change?
- What is Iovance Biotherapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics TTM EBIT year-on-year change?
What is Iovance Biotherapeutics annual earnings before interest & taxes?
The current annual EBIT of IOVA is -$460.56 M
What is the all time high annual EBIT for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high annual earnings before interest & taxes is -$14.40 K
What is Iovance Biotherapeutics annual EBIT year-on-year change?
Over the past year, IOVA annual earnings before interest & taxes has changed by -$61.68 M (-15.46%)
What is Iovance Biotherapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of IOVA is -$89.07 M
What is the all time high quarterly EBIT for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high quarterly earnings before interest & taxes is $5.06 M
What is Iovance Biotherapeutics quarterly EBIT year-on-year change?
Over the past year, IOVA quarterly earnings before interest & taxes has changed by +$29.29 M (+24.75%)
What is Iovance Biotherapeutics TTM earnings before interest & taxes?
The current TTM EBIT of IOVA is -$429.96 M
What is the all time high TTM EBIT for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high TTM earnings before interest & taxes is $4.09 M
What is Iovance Biotherapeutics TTM EBIT year-on-year change?
Over the past year, IOVA TTM earnings before interest & taxes has changed by +$16.38 M (+3.67%)